Key Highlights

  • The US Nuclear Regulatory Commission released the final environmental impact statement for the Paducah Laser Enrichment Facility on 27 October 2026.
  • The facility is proposed by Global Laser Enrichment, in which Silex holds 51%.
  • A safety evaluation report must still be completed before the construction and operating licence can be issued.
  • Commercial production is not planned before 2030, and these dates are company expectations.

How close is Silex Systems (ASX:SLX) to turning its laser uranium enrichment technology into a commercial plant? The most recent milestone came on 27 October 2026, when the US Nuclear Regulatory Commission (NRC) released the final environmental impact statement (EIS) for the Paducah Laser Enrichment Facility in Kentucky. The facility is proposed by Global Laser Enrichment (GLE), in which Silex holds 51%. The EIS is a necessary step toward a licence, though not the last one, and commercial production is not planned before 2030.

The central development

The final EIS followed on 27 October 2026. GLE and Silex say it supports issuing a construction licence. Silex expects that report before the end of 2026 and licence approval in 2027, with the facility targeted to begin operations in 2030. These dates are company expectations, not regulatory commitments.

The proposed plant would re-enrich depleted uranium hexafluoride tails and enrich natural-grade material to a maximum of 8% U-235. The application covers up to 2,000 metric tons per year of natural UF6 equivalent and 6 million separative work units (SWU) per year of low-enriched uranium. GLE acquired a 665-acre site next to the former Paducah Gaseous Diffusion Plant in November 2024.

What Silex does and how it earns

Silex is a technology developer. Its SILEX laser enrichment process is licensed to GLE, a joint venture with Cameco (49%). Silex's Revenue is therefore small and lumpy: licence-related milestone payments and other income, not product sales. In FY26 (year ended 30 June 2026), the company reported:

Revenue from continuing operations of A$21.6m, up from A$12.2m, with milestone revenue of A$7.6m the main driver.

Other income of A$5.2m, down from A$6.4m on a lower R&D tax incentive.

A loss before tax of A$38.6m, narrowed from A$42.6m, after a larger A$45.5m share of GLE's loss.

Cash and term deposits of about A$180.7m at 30 June 2026, with no corporate debt.

Net Assets of A$201.2m, up 121%, largely reflecting the August 2025 Capital raise.

No dividend.

These are figures from the company's results documentation. The Business remains loss-making and will likely stay so until GLE generates commercial revenue, which is a multi-year proposition.

Funding and partner support

GLE paid a US$5m milestone in December 2025, with a further US$15m of milestone payments provided for under the licence. In October 2025 independent validation confirmed the technology reached technology readiness level 6 (TRL-6), a large-scale pilot demonstration. Cameco holds an option to buy an additional 26% of GLE, exercisable until April 2028. In January 2026 the US Department of Energy selected GLE for a US$28.5m funding award, and in March 2026 Kentucky and McCracken County gave preliminary approval for incentives of up to US$98.9m, subject to Investment and employment thresholds. GLE targets commercial operations by 2030, subject to a feasibility study and a final investment decision, neither of which has been made.

Quantum Silicon

Separately, Silex is developing Quantum Silicon (Q-Si), a high-purity silicon for quantum computing. The Sydney production plant was completed in June 2026, with integration and commissioning continuing. Sample production is expected in the first quarter of calendar 2027, with capacity of up to 20kg a year.

Sector and competitive position

Uranium enrichment is dominated by a small group of state-linked suppliers, and Western governments have been seeking additional domestic and non-Russian Supply capacity. That policy backdrop supports Demand for new enrichment capacity, and the DOE award is an example. Silex's laser technology competes with established centrifuge technology, and other groups are pursuing enrichment projects in the United States. The main competitive question is whether SILEX can demonstrate lower cost or other advantages at commercial scale, which has not yet been proven.

Material risks

Technology risk: the process has to perform at commercial scale, and the company says its maturation will be independently assessed.

Funding and FID risk: construction is subject to a feasibility study and final investment decision, and large capital will be needed.

Market risk: fuel market conditions, demand and offtake agreements could change; customers may default or contracts may be hard to enforce.

Geopolitical risk: sovereign risk and tariffs are listed among the company's risks.

Competition and IP: rivals and intellectual property protection matter for a technology licensor.

Key staff and operational risks, including cyber security and safety.

What to monitor

The half-year result to 31 December 2026 will show the cash burn.

Silex's story is regulatory and technical progress with long timelines. Recent milestones are real, but they leave most of the commercial risk still ahead.